WTO Relative Valuation
WTO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, WTO is overvalued; if below, it's undervalued.
Historical Valuation
UTime Ltd (WTO) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 0.00. The fair price of UTime Ltd (WTO) is between -- to -- according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：0.69
Fair
0.00
PE
1Y
3Y
5Y
0.00
EV/EBITDA
UTime Ltd. (WTO) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.
0.00
EV/EBIT
UTime Ltd. (WTO) has a current EV/EBIT of 0.00. The 5-year average EV/EBIT is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBIT of 0.00 falls within the Strongly Undervalued range.
0.00
PS
UTime Ltd. (WTO) has a current PS of 0.00. The 5-year average PS is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward PS of 0.00 falls within the Strongly Undervalued range.
0.00
P/OCF
UTime Ltd. (WTO) has a current P/OCF of 0.00. The 5-year average P/OCF is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward P/OCF of 0.00 falls within the Strongly Undervalued range.
0.00
P/FCF
UTime Ltd. (WTO) has a current P/FCF of 0.00. The 5-year average P/FCF is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward P/FCF of 0.00 falls within the Strongly Undervalued range.
UTime Ltd (WTO) has a current Price-to-Book (P/B) ratio of -0.00. Compared to its 3-year average P/B ratio of 1.59 , the current P/B ratio is approximately -100.10% higher. Relative to its 5-year average P/B ratio of 4.00, the current P/B ratio is about -100.04% higher. UTime Ltd (WTO) has a Forward Free Cash Flow (FCF) yield of approximately -277.80%. Compared to its 3-year average FCF yield of -372.12%, the current FCF yield is approximately -25.35% lower. Relative to its 5-year average FCF yield of -238.61% , the current FCF yield is about 16.43% lower.
-0.00
P/B
Median3y
1.59
Median5y
4.00
-277.80
FCF Yield
Median3y
-372.12
Median5y
-238.61
Competitors Valuation Multiple
The average P/S ratio for WTO's competitors is 0.13, providing a benchmark for relative valuation. UTime Ltd Corp (WTO) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
1Y
3Y
5Y
Market capitalization of WTO increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of WTO in the past 1 year is driven by Unknown.
People Also Watch
PAVM
PAVmed Inc
7.29USD
-1.22%
STRR
Star Equity Holdings Inc
10.73USD
0.66%
WAFU
Wah Fu Education Group Ltd
1.62USD
-0.61%
CNSP
CNS Pharmaceuticals Inc
5.94USD
7.22%
KAVL
Kaival Brands Innovations Group Inc
0.187USD
-13.97%
JCSE
JE Cleantech Holdings Ltd
2.48USD
7.83%
ENSC
Ensysce Biosciences Inc
1.06USD
-0.93%
RDHL
Redhill Biopharma Ltd
1.34USD
9.84%
Frequently Asked Questions
Is UTime Ltd (WTO) currently overvalued or undervalued?
UTime Ltd (WTO) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 0.00. The fair price of UTime Ltd (WTO) is between to according to relative valuation methord.
What is UTime Ltd (WTO) fair value?
WTO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of UTime Ltd (WTO) is between to according to relative valuation methord.
How does WTO's valuation metrics compare to the industry average?
The average P/S ratio for WTO's competitors is 0.13, providing a benchmark for relative valuation. UTime Ltd Corp (WTO) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for UTime Ltd (WTO) as of Jan 08 2026?
As of Jan 08 2026, UTime Ltd (WTO) has a P/B ratio of -0.00. This indicates that the market values WTO at -0.00 times its book value.
What is the current FCF Yield for UTime Ltd (WTO) as of Jan 08 2026?
As of Jan 08 2026, UTime Ltd (WTO) has a FCF Yield of -277.80%. This means that for every dollar of UTime Ltd’s market capitalization, the company generates -277.80 cents in free cash flow.
What is the current Forward P/E ratio for UTime Ltd (WTO) as of Jan 08 2026?
As of Jan 08 2026, UTime Ltd (WTO) has a Forward P/E ratio of 0.00. This means the market is willing to pay $0.00 for every dollar of UTime Ltd’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for UTime Ltd (WTO) as of Jan 08 2026?
As of Jan 08 2026, UTime Ltd (WTO) has a Forward P/S ratio of 0.00. This means the market is valuing WTO at $0.00 for every dollar of expected revenue over the next 12 months.